Eli Lilly Is A Hold On Valuation Following Q2 Report : vimarsana.com

Eli Lilly reported its Q2 results, showing a revenue decline. LLY shares are trading for almost 40 times forward earnings. Read our analysis here.

Related Keywords

China , Indiana , United States , Japan , Dave Ricks , Eli Lilly , Dan Skovronsky , Seeking Alpha , Anat Ashkenazi , Chief Scientific Officer , Chief Medical Officer ,